An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders
Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary
NexImmune Inc. has announced a service agreement with Selexis SA to develop cell lines targeting rare cancers and autoimmune diseases. This collaboration aims to advance two human leukocyte antigens (HLAs) using Selexis' SURE technology, which enhances efficiency in cell line development. The resulting cell lines will aid in manufacturing innovative therapeutic products designed to utilize T cell immunotherapy for patients.
This partnership signifies a continued commitment to improving treatment options for challenging diseases, highlighting NexImmune's long-term strategy in advancing its proprietary AIM injectable nanoparticles.
Positive
Partnership with Selexis could significantly enhance development efficiency for NexImmune's therapies.
Collaboration supports the advancement of novel immunotherapies aimed at rare cancers and autoimmune diseases.
Utilization of Selexis' SURE technology may reduce time and costs associated with cell line development.
Negative
None.
Agreement supports the development of molecules targeting acute myeloid leukemia, multiple myeloma, human papilloma virus (HPV) associated tumors, and additional human leukocyte antigens (HLAs) that have the potential to increase immunotherapy options for patients
GENEVA & GAITHERSBURG, Md.--(BUSINESS WIRE)--
Selexis SA, a JSR Life Sciences company, and NexImmune Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies, announced today that they have signed a service agreement to develop cell lines targeting rare cancers and autoimmune diseases and to advance two HLAs that can be used to expand treatments to more patients. Per the agreement, NexImmune will leverage Selexis’ SUREtechnology Platform™, a suite of cell line development technologies that significantly reduce the time, effort, and costs associated with developing high-performance mammalian cell lines.
The Selexis-generated cell lines will be used to manufacture HLA IgG4 fusion proteins and T cell co-stimulatory monoclonal antibodies that will be incorporated into NexImmune’s proprietary AIM injectable nanoparticle modality. These nanoparticles are designed to be an off-the-shelf injectable modality to engage a patient’s own T cells to identify and kill a variety of diseased cells within the body.
“We are pleased to support NexImmune’s exciting programs. Its innovative T cell modulating nanotechnology has the potential to create therapies that provide better outcomes for patients suffering from rare forms of cancer and autoimmune diseases,” said Mark W. Womack, Chief Executive Officer of Selexis and KBI Biopharma. “We are excited to continue our longstanding relationship with NexImmune and are proud to be its cell line development provider of choice. We look forward to helping advance their novel immunotherapies to the clinic.”
NexImmune’s off-the-shelf AIM injectable nanoparticles, decorated with antigen-specific peptides and co-stimulatory molecules, have the ability to engage antigen-specific T cell populations at multiple sites in the body and specifically stimulate or tolerize them to address a range of diseases, including cancers and autoimmune disorders for which there are currently no effective cellular therapies available.
“We are thrilled to have a partner in Selexis, as an industry-leading cell line development provider,” said NexImmune Chief Scientific Officer, Mathias Oelke. “Our long-established working relationship made the decision to partner with them again an easy choice. We look forward to working together as we develop biologics that have the potential to make a real difference in patients’ lives.”
About Selexis SA
Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global client partners have utilized Selexis technologies to advance more than 160 drug candidates in preclinical and clinical development and manufacture ten commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com
About NexImmune
NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent, and durable immune response. NexImmune’s lead programs, NEXI-001, NEXI-002 and NEXI-003, are in Phase 1/2 clinical trials for the treatment of relapsed AML after allogeneic stem cell transplantation, multiple myeloma refractory to 3 or more prior lines of therapy and HPV-related cancers, respectively. NexImmune is also developing AIM nanoparticle constructs and modalities for potential clinical evaluation in oncology and in disease areas outside of oncology, including autoimmune disorders and infectious disease.
The backbone of NexImmune’s approach is a proprietary Artificial Immune Modulation (AIM™) nanoparticle technology platform. The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. NexImmune’s nanoparticles employ natural biology to engage, activate and expand endogenous T cells in ways that combine anti-tumor attributes of antigen-specific precision, potency and long-term persistence with reduced potential for off-target toxicities. Alternatively for autoimmune indications, NexImmune’s nanoparticles can engage antigen specific autoreactive cells to tolerize or kill cells responsible for disease without broad immunosuppression.For more information, visit www.neximmune.com.
What is the recent agreement between NexImmune and Selexis about?
NexImmune and Selexis have signed a service agreement to develop cell lines targeting rare cancers and autoimmune diseases, utilizing Selexis' SURE technology.
How will the agreement impact NexImmune's immunotherapy development?
The collaboration with Selexis is expected to accelerate the development of NexImmune’s innovative therapies for patients suffering from rare forms of cancer and autoimmune diseases.
What technology will be used in the NexImmune and Selexis partnership?
The partnership will leverage Selexis' SURE technology, which improves the efficiency of developing high-performance mammalian cell lines.
What diseases are targeted by NexImmune's new therapies?
NexImmune's new therapies aim to target rare cancers, including acute myeloid leukemia, multiple myeloma, and HPV-associated tumors.
